Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Capital Expenditures: 2017-2025

Historic Capital Expenditures for Aclaris Therapeutics (ACRS) over the last 7 years, with Sep 2025 value amounting to $23,000.

  • Aclaris Therapeutics' Capital Expenditures was N/A to $23,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $73,000, marking a year-over-year change of. This contributed to the annual value of $121,000 for FY2024, which is 90.76% down from last year.
  • Latest data reveals that Aclaris Therapeutics reported Capital Expenditures of $23,000 as of Q3 2025, which was up 9.52% from $21,000 recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Capital Expenditures ranged from a high of $553,000 in Q1 2023 and a low of -$14,000 during Q2 2024.
  • Moreover, its 3-year median value for Capital Expenditures was $84,000 (2023), whereas its average is $168,556.
  • As far as peak fluctuations go, Aclaris Therapeutics' Capital Expenditures spiked by 2,400.00% in 2021, and later tumbled by 106.06% in 2024.
  • Aclaris Therapeutics' Capital Expenditures (Quarterly) stood at $200,000 in 2021, then slumped by 47.50% to $105,000 in 2022, then surged by 320.00% to $441,000 in 2023, then slumped by 106.06% to -$14,000 in 2024, then surged by 250.00% to $23,000 in 2025.
  • Its Capital Expenditures was $23,000 in Q3 2025, compared to $21,000 in Q2 2025 and $43,000 in Q1 2025.